Cargando…

Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis

BACKGROUND: Lung disease phenotype varies widely even in the F508del (homozygous) genotype. Leukocyte-driven inflammation is important for pulmonary disease pathogenesis in cystic fibrosis (CF). Blood cytokines correlate negatively with pulmonary function in F508del homozygous patients, and gap junc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horn, Tabea, Ludwig, Michael, Eickmeier, Olaf, Neerinex, Anne H., Maitland-van der Zee, Anke H., Smaczny, Christina, Wagner, Thomas O. F., Schubert, Ralf, Zielen, Stefan, Majoor, Christof, Bos, Lieuwe D., Schmitt-Grohé, Sabina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655539/ https://www.ncbi.nlm.nih.gov/pubmed/33193670 http://dx.doi.org/10.3389/fgene.2020.570403

Ejemplares similares

Connexin 37 and Connexin 43 genotypes in correlation to cytokines in induced sputum and blood in cystic fibrosis (CF)
por: Ludwig, M, et al.
Publicado: (2014)

Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung disease in cystic fibrosis
por: Eickmeier, Olaf, et al.
Publicado: (2017)

Transforming Growth Factor β1 Genotypes in Relation to TGFβ1, Interleukin-8, and Tumor Necrosis Factor Alpha in Induced Sputum and Blood in Cystic Fibrosis
por: Eickmeier, O., et al.
Publicado: (2013)

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
por: Neerincx, Anne H., et al.
Publicado: (2021)

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability
por: Vonk, Steffie E. M., et al.
Publicado: (2021)

Two Siblings Homozygous for F508del-CFTR Have Varied Disease Phenotypes and Protein Biomarkers
por: Zhang, Zhihong, et al.
Publicado: (2021)

Oxidative stress-driven pulmonary inflammation and fibrosis in a mouse model of human ataxia-telangiectasia
por: Duecker, Ruth, et al.
Publicado: (2017)

Impact of CFTR Modulators on the Impaired Function of Phagocytes in Cystic Fibrosis Lung Disease
por: Meoli, Aniello, et al.
Publicado: (2022)

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
por: Kos, Renate, et al.
Publicado: (2022)

A specific combined long-chain polyunsaturated fatty acid supplementation reverses fatty acid profile alterations in a mouse model of chronic asthma
por: Fussbroich, D., et al.
Publicado: (2019)

Precision Medicine in Neonates: Future Perspectives for the Lung
por: Onland, Wes, et al.
Publicado: (2020)

DeltaF508 CFTR Hetero- and Homozygous Paediatric Patients with Cystic Fibrosis Do Not Differ with Regard to Nutritional Status
por: Mędza, Aleksandra, et al.
Publicado: (2021)

Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients
por: Yaacoby-Bianu, Karin, et al.
Publicado: (2022)

P079 Real-life data on the efficacy and safety of tezacaftor/ivacaftor in people living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation
por: Vincken, S., et al.
Publicado: (2022)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators
por: Muilwijk, Danya, et al.
Publicado: (2021)

Altered mucosal immune response after acute lung injury in a murine model of Ataxia Telangiectasia
por: Eickmeier, Olaf, et al.
Publicado: (2014)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
por: Berges, Julian, et al.
Publicado: (2023)

Tiotropium as an Add-on Treatment Option for Severe Uncontrolled Asthma in Preschool Patients
por: Zielen, Stefan, et al.
Publicado: (2021)

Tensin 1 (TNS1) is a modifier gene for low body mass index (BMI) in homozygous [F508del]CFTR patients
por: Walton, Nathan I., et al.
Publicado: (2021)

Answer to the question page 508
Publicado: (2012)

Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi(®)) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
por: Favia, Maria, et al.
Publicado: (2020)

Cystic Fibrosis: Systems Biology Analysis from Homozygous p.Phe508del Variant Patients' Samples Reveals Perturbations in Tissue-Specific Pathways
por: de Faria Poloni, Joice, et al.
Publicado: (2021)

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
por: Carnovale, Vincenzo, et al.
Publicado: (2022)

Effect of thrombin peptide 508 (TP508) on bone healing during distraction osteogenesis in rabbit tibia
por: Amir, Lisa R., et al.
Publicado: (2007)

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR
por: Rayment, Jonathan H., et al.
Publicado: (2022)

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
por: Pohl, Kerstin, et al.
Publicado: (2018)

Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial
por: Stahl, Mirjam, et al.
Publicado: (2023)

Accessibility handbook: making 508 websites for everyone
por: Cunningham, Katie
Publicado: (2012)

I4 Hotspot: runs 505 and 508
por: Risselada, Thys
Publicado: (1974)

Production of CFTR-ΔF508 Rabbits
por: Yang, Dongshan, et al.
Publicado: (2021)

Consistent Assignment of Risk and Benign Allele at rs2303153 in the CF Modifier Gene SCNN1B in Three Independent F508del-CFTR Homozygous Patient Populations
por: Stanke, Frauke, et al.
Publicado: (2021)

Decoding F508del Misfolding in Cystic Fibrosis
por: Wang, Xiaodong Robert, et al.
Publicado: (2014)

Recovery of ΔF508-CFTR Function by Citrate
por: Borkenhagen, Beatrice, et al.
Publicado: (2022)

FRI508 A Case Of Durvalumab Induced Hypothyroidism
por: Cecilio La Riva, Estefania Del Valle, et al.
Publicado: (2023)

Influence of bacterial and alveolar cell co-culture on microbial VOC production using HS-GC/MS
por: Fenn, Dominic, et al.
Publicado: (2023)

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
por: Mainz, Jochen G., et al.
Publicado: (2022)

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
por: Mainz, Jochen G., et al.
Publicado: (2023)

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry
por: Sutharsan, Sivagurunathan, et al.
Publicado: (2023)

Identification and selection of healthy spermatozoa in heterozygous carriers of the Phe508del-variant of the CFTR-gene in assisted reproduction
por: De Geyter, Julie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pndq461mcpicgfcpplin54a9j7